Michael Pugia, PhD
Investigator and Director, Bioanalytical Technologies
Michael Pugia, Ph.D., is an Investigator and Director of the IBRI's Bioanalytical Technologies group, effective May 2019. Before that, he served as Director of the Single Cell Analytics Center. Pugia spent 30 years in the biomedical in-vitro diagnostic industry where he contributed to more than 20 new product launches for Bayer and Siemens. He spent 15 years as a director of research and development working on next generation analytical and diagnostic technologies in collaboration with leading institutions and companies. Pugia’s primary research interest is the development of single-cell bioanalytical technology for proteomic biomarkers discovery in the fields of endocrinology and oncology.
In 2009, Pugia was awarded the Siemens Inventor of the Year for his work on a miniaturized “lab-on-a-chip” diagnostic tool. He also was recognized with nine Bayer Science and Technology Awards including the Outstanding Bayer Technology Award, the Bayer Corp Quality Excellence Award, and the Near Patient Testing Segment General Manager Award for Exceptional Leadership. The American Association of Chemistry honored him as the Samuel Natelson Senior Investigator in recognition of outstanding service for the advancement of clinical chemistry, and as the winner of the 1st Annual AI Free Memorial Lectureship.
Pugia holds 56 U.S. patents and has 34 active U.S. patent applications with more than 470 worldwide patent filings. He also has 55 manuscripts, 15 book chapters and hundreds of conference papers and lectures in a wide variety of chemistry disciplines to his name. He earned his Ph.D. in chemistry from Texas Tech University and his bachelor’s degree in chemistry from Clarkson University. While working in industry, Pugia has held adjunct positions as a Visiting Scholar at the University of Notre Dame and as a Clinical Research Professor at the University of Louisville Medical School.